Back
Bio-Techne 10K Form
Buy
60
TECH
Bio-Techne
Last Price:
77.31
Seasonality Move:
10.64%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-07 | 10Q | TECH/Bio-Techne Quarterly |
2023-05-08 | 10Q | TECH/Bio-Techne Quarterly |
2023-02-07 | 10Q | TECH/Bio-Techne Quarterly |
2022-11-07 | 10Q | TECH/Bio-Techne Quarterly |
2022-05-09 | 10Q | TECH/Bio-Techne Quarterly |
2022-02-07 | 10Q | TECH/Bio-Techne Quarterly |
Receive TECH News And Ratings
See the #1 stock for the next 7 days that we like better than TECH
TECH Financial Statistics
Sales & Book Value
Annual Sales: | $1.14B |
---|---|
Cash Flow: | $64.55M |
Price / Cash Flow: | 48.51 |
Annual Sales: | $12.81 |
Price / Book: | 5.9 |
Profitability
EPS (TTM): | 1.26000 |
---|---|
Net Income (TTM): | $203M |
Gross Margin: | $769.82M |
Return on Equity: | 10.32% |
Return on Assets: | 7.55% |
Bio-Techne Earnings Forecast
Key Bio-Techne Financial Ratios
- The Gross Profit Margin over the past 35 years for TECH is 67.72%.
- The Selling, General & Administrative Expenses for TECH have been equal to 31.01% of Gross Profit Margin.
- The Research & Development expenses have been 8.14% of Revenue.
- The Interest Expense is 3.93% of Operating Income.
- The Net Earning history of TECH is 25.10% of Total Revenues.
- Per Share Earnings over the last 35 years have been positive in 27 years.
Bio-Techne Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Life Sciences Tools & Services |
Sector: | Health Care |
Current Symbol: | TECH |
CUSIP: | 09073M |
Website: | bio-techne.com |
Debt
Debt-to-Equity Ratio: | 0.19 |
---|---|
Current Ratio: | 4.08 |
Quick Ratio: | 2.49 |
Price-to-Earnings
Trailing P/E Ratio: | 42.95 |
---|---|
Forward P/E Ratio: | 37.07 |
TECH Technical Analysis vs Fundamental Analysis
Buy
60
Bio-Techne (TECH)
is a Buy
Is Bio-Techne a Buy or a Sell?
-
Bio-Techne stock is rated a Buy
The current Bio-Techne [TECH] share price is $75.60. The Score for TECH is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.